All In Biotech

NDA 202057 · Amarin Pharms

Vascepa

Icosapent Ethyl · Oral

Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Jul 26, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

57

21 Phase 3, 1 recruiting

FAERS reports

8,228

2,986 serious, 422 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 7, 2026.

VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels(≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. ( 1 ) as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. ( 1 ) Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. ( 1 )

Mechanism: Studies suggest that EPA reduces hepatic very low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver; and increased plasma lipoprotein lipase activity. The mechanisms of action contributing to reduction of cardiovascular events with VASCEPA (icosapent ethyl) are not completely understood but are likely multi-factorial. Increased EPA lipid composition from...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VASCEPA · ICOSAPENT ETHYL 500MG · CAPSULE, ORAL · Prescription · TE AB
  • VASCEPA · ICOSAPENT ETHYL 1GM · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Icosapent Ethyl" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product odour abnormal1,055
  • product physical issue915
  • off label use675
  • poor quality product administered668
  • diarrhoea525
  • nausea504
  • product taste abnormal451
  • drug ineffective450
  • arthralgia399
  • fatigue350
  • blood triglycerides increased305
  • eructation281

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20125
201375
2014102
2015208
2016207
2017350
2018391
2019659
2020939
20211,176
2022801
2023772
2024759
2025952
2026831

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Vascepa (Icosapent Ethyl)

2024 spending

$724M

Beneficiaries

301,070

1,474,990 claims

Per beneficiary

$2,405

$2.87 per unit

View as table
YearSpending
2020$754,811,701
2021$831,994,328
2022$787,854,458
2023$763,988,447
2024$724,180,334

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 60 on PubMed

Sponsor: Amarin Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.